Beyond NKt-AML, our analysis indicates that other AML subtypes, particularly t(6;9) and t(8;21) AML, also express significant levels of IL1RAP, suggesting potential broader applications for IL1RAP-targeted therapies. This evidence concerns the gene IL1RAP and acute myeloid leukemia.